Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Graham McClorey"'
Autor:
Ysobel R. Baker, Cameron Thorpe, Jinfeng Chen, Laura M. Poller, Lina Cox, Pawan Kumar, Wooi F. Lim, Lillian Lie, Graham McClorey, Sven Epple, Daniel Singleton, Michael A. McDonough, Jack S. Hardwick, Kirsten E. Christensen, Matthew J. A. Wood, James P. Hall, Afaf H. El-Sagheer, Tom Brown
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Oligonucleotides targeting mRNA are promising therapeutic agents but suffer from poor bioavailability. Here, the authors develop reduced-charge oligonucleotides with artificial LNA-amide linkages with improved cell uptake and minimal structural devia
Externí odkaz:
https://doaj.org/article/9f5986b8806645e7a8826174637171fa
Autor:
Tirsa L.E. vanWestering, Yulia Lomonosova, Anna M.L. Coenen‐Stass, Corinne A. Betts, Amarjit Bhomra, Margriet Hulsker, Lucy E. Clark, Graham McClorey, Annemieke Aartsma‐Rus, Maaike vanPutten, Matthew J.A. Wood, Thomas C. Roberts
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 11, Iss 2, Pp 578-593 (2020)
Abstract Background Duchenne muscular dystrophy (DMD) is a fatal muscle‐wasting disorder caused by genetic loss of dystrophin protein. Extracellular microRNAs (ex‐miRNAs) are putative, minimally invasive biomarkers of DMD. Specific ex‐miRNAs (e
Externí odkaz:
https://doaj.org/article/f3627d2febcc4bb89cb45a178fc1a87b
Autor:
Alison M Blain, Elizabeth Greally, Graham McClorey, Raquel Manzano, Corinne A Betts, Caroline Godfrey, Liz O'Donovan, Thibault Coursindel, Mike J Gait, Matthew J Wood, Guy A MacGowan, Volker W Straub
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0198897 (2018)
Cardiac failure is a major cause of mortality in patients with Duchenne muscular dystrophy (DMD). Antisense-mediated exon skipping has the ability to correct out-of-frame mutations in DMD to produce truncated but functional dystrophin. Traditional an
Externí odkaz:
https://doaj.org/article/3ba329284b914067ab2dc83073aab5b6
Autor:
Suzan M Hammond, Graham McClorey, Joel Z Nordin, Caroline Godfrey, Sofia Stenler, Kim A Lennox, CI Edvard Smith, Ashley M Jacobi, Miguel A Varela, Yi Lee, Mark A Behlke, Matthew J A Wood, Samir E L Andaloussi
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 3, Iss C (2014)
Splice switching oligonucleotides (SSOs) induce alternative splicing of pre-mRNA and typically employ chemical modifications to increase nuclease resistance and binding affinity to target pre-mRNA. Here we describe a new SSO non-base modifier (a naph
Externí odkaz:
https://doaj.org/article/610e0a409d3146f7beb11ae6ad8495ab
Autor:
Thomas C Roberts, K Emelie M Blomberg, Graham McClorey, Samir EL Andaloussi, Caroline Godfrey, Corinne Betts, Thibault Coursindel, Michael J Gait, CI Edvard Smith, Matthew JA Wood
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 1, Iss C (2012)
MicroRNAs (miRNAs) are a class of small RNAs that regulate gene expression and are implicated in wide-ranging cellular processes and pathological conditions including Duchenne muscular dystrophy (DMD). We have compared differential miRNA expression i
Externí odkaz:
https://doaj.org/article/e9477d02be4e40489e38f8dbfc780860
Autor:
Alberto Malerba, Jagjeet K Kang, Graham McClorey, Amer F Saleh, Linda Popplewell, Michael J Gait, Matthew JA Wood, George Dickson
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 1, Iss C (2012)
The knockdown of myostatin, a negative regulator of skeletal muscle mass may have important implications in disease conditions accompanied by muscle mass loss like cancer, HIV/AIDS, sarcopenia, muscle atrophy, and Duchenne muscular dystrophy (DMD). I
Externí odkaz:
https://doaj.org/article/58a7f59b4ffc4b1299392e488bfee511
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 1, Iss C (2012)
Myostatin (Mstn) is a secreted growth factor that negatively regulates muscle mass and is therefore a potential pharmacological target for the treatment of muscle wasting disorders such as Duchenne muscular dystrophy. Here we describe a novel Mstn bl
Externí odkaz:
https://doaj.org/article/1a5b9914b7f84a9a95242b647a634a0c
Publikováno v:
PLoS Genetics, Vol 3, Iss 6, p e109 (2007)
Conventional gene therapy has focused largely on gene replacement in target cells. However, progress from basic research to the clinic has been slow for reasons relating principally to the challenges of heterologous DNA delivery and regulation in viv
Externí odkaz:
https://doaj.org/article/e660a0ca8a484574a4f7222dac1d75b2
Autor:
Katarzyna Chwalenia, Jacopo Oieni, Joanna Zemła, Małgorzata Lekka, Nina Ahlskog, Anna M.L. Coenen-Stass, Graham McClorey, Matthew J.A. Wood, Yulia Lomonosova, Thomas C. Roberts
Publikováno v:
Molecular Therapy - Nucleic Acids. 29:955-968
Therapies that restore dystrophin expression are presumed to correct Duchenne muscular dystrophy (DMD), with antisense-mediated exon skipping being the leading approach. Here we aimed to determine whether exon skipping using a peptide-phosphorodiamid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e47664f37750961bbc66d53ae1356845
https://doi.org/10.1016/j.omtn.2022.08.033
https://doi.org/10.1016/j.omtn.2022.08.033
Autor:
Ysobel Baker, Cameron Thorpe, Jinfeng Chen, Laura Poller, Lina Cox, Pawan Kumar, Wooi Fang Lim, Lillian Lie, Graham McClorey, Sven Epple, Daniel Singleton, Michael McDonough, Jack Hardwick, Kirsten Christensen, Matthew Wood, James Hall, Afaf El-Sagheer, Tom Brown
Oligonucleotides that target mRNA have great promise as therapeutic agents for life-threatening conditions but suffer from poor bioavailability, hence high cost. As currently untreatable diseases come within the reach of oligonucleotide therapies, ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c992ec0a712366c4f42d75cb08d36fa4
https://doi.org/10.21203/rs.3.rs-1542733/v1
https://doi.org/10.21203/rs.3.rs-1542733/v1
